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Background
The increasing trend in antibiotic resistance continues to
threaten global health due to the limited pipeline of new anti-
biotics. Multidrug resistance in Gram-negative bacteria is of
special concern because it may associate resistance to the three
main classes of antibiotics in single isolates. These three classes
are: (i) the β-lactams with plasmid-encoded extended-spectrum
β-lactamases (ESBLs) hydrolysing cephalosporins and with
carbapenemases hydrolysing additionally carbapenems, (ii) the
aminoglycosides with 16S rRNA methylases modifying their
cellular target and conferring pan-aminoglycoside resistance,
and (iii) the ﬂuoroquinolones mostly with topoisomerase mu-
tations. Due to the paucity of remaining antibiotics for treating
infections, polymyxins (colistin, polymyxin B) have become the
last resort, in particular for treating infections due to
carbapenem-resistant Enterobacteriaceae. Polymyxins, although
introduced to the antibiotic armamentarium in the 1950s, have
been considered until recently to be too nephrotoxic and too
neurotoxic for their regular use for treating infections in
humans [1]. Their large usage was restricted to animals.
Now, plasmid-encoded colistin resistance mediated by the
mobile colistin resistance-1 (MCR-1) protein has been identi-
ﬁed from human, animal and environmental isolates from
China, as published in November 2015 [2]. MCR-1 is a phos-
phoethanolamine transferase that catalyses the addition of a
phosphoethanolamine group to lipid A, leading to a decreased
afﬁnity of colistin for the lipopolysaccharide [2]. Resistance to
colistin is not new; numerous bacterial species are intrinsically
resistant to colistin and acquired resistance has been selected
on chromosomal mutations [1]. What is new here is the
plasmid location of the colistin resistance trait and hence its
interspecies transferability. Soon after the pioneering Chinese
work had led to the identiﬁcation of MCR-1, the same mcr-1
gene was identiﬁed on all continents, in animals, human isolates,
food and environmental samples, mostly in Escherichia coli
[3–7]. Several pieces of evidence suggest that the reservoir of
the mcr-1 gene is in animals as follows: (i) the heavy usage of
polymyxins in animals as growth promoter, prophylaxis and
metaphylaxis, and their curative usage mostly in pigs, chickens
and cattle that constitute a driving force for selection of MCR-
1-producers [1,2]; (ii) the identiﬁcation so far of the mcr-1 gene
being mostly from animal isolates (20% among animal isolates,
compared with 1% among human isolates in China from 2011
to 2014) [1]; (iii) the identiﬁcation of the ﬂorfenicol resistance
gene, ﬂoR, in MCR-1 producers when ﬂorfenicol is given only to
animals [3]; (iv) the genetic association of the mcr-1 gene with
insertion sequence ISApl1 originating from Pasteurella multocida,
a common pathogen for animals [3]; and (v) the association of
MCR-1 with plasmid-mediated cephalosporinase, CMY-2,
which is known to be widespread in animal isolates [4].
How Worried Should We Be About MCR-1?
The pessimistic viewpoint of this issue can be summarized as
follows. Transfer of the mcr-1 gene to carbapenemase producers
in nosocomial settings may ensure the apocalypse of antibiotics.
Indeed, a community-acquired E. coli isolate producingMCR-1 and
the carbapenemase Verona imipenemase-1 (VIM-1) [3], an E. coli
isolate expressing MCR-1 and Klebsiella pneumoniae carbapene-
mase-2 (KPC-2) [4], and a Klebsiella pneumoniae isolate producing
MCR-1 and New Delhi metallo enzyme-5 (NDM-5) [5] have
already been identiﬁed. The mcr-1 gene may be identiﬁed in bac-
teria responsible for severe infections such as bacteraemia as
evidenced recently in Switzerland [6]. The spread of MCR-1 has
already occurred on a large scale with its simultaneous identiﬁ-
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cation worldwide in the environment, community-acquired and
hospital-acquired pathogens and animals. The animal reservoir
may already be important. This animal, and possible environ-
mental, reservoir will be difﬁcult to control compared with any
emerging hospital-acquired resistance determinant. Worringly,
E. coli being the main host of MCR-1, is one of the bacterial species
that is the most widely distributed and exchanged between the
environment, animals and humans. Spread of the MCR-1 deter-
minant may follow the same trend as that observed for ESBLs of
the CTX-M type two decades ago, ﬁrst located in E. coli then in
nosocomial species such as in K. pneumoniae as a source of mul-
tiple outbreaks. The identiﬁcation of the mcr-1 gene on several
plasmid backbones suggests that its spread corresponds to mul-
tiple genetic events that have occurred independently in distantly
related geographical areas. Several genetic analyses have already
indicated that the mcr-1 gene is located on transferable plasmids
increasing the variety of potential transmission vectors. Detection
of MCR-1 producers may be difﬁcult because MCR-1 confers a
low level of resistance to colistin [2–7] (4–16 mg/L with a
breakpoint value of 2 mg/L according to the EUCAST guidelines)
and colistin susceptibility remains difﬁcult to determine in routine
microbiology [1].
In contrast, the optimistic point of viewmay be summarized as
follows. The MCR-1 determinant seems to be so far mostly
located in animal isolates and not in human isolates. The true
prevalence of MCR-1-producing isolates is difﬁcult to estimate
andmay be very low in geographical areas such as the USAwhere
polymyxin is not used in animals. It is not a true emerging
resistance trait because MCR-1-producing isolates collected as
early as 2005 have already been identiﬁed [7]. Many of the MCR-
1 producers still remain susceptible to antibiotics such as ceph-
alosporins and carbapenems, leaving many treatment options
[2–7]. Escherichia coli, as the main target of MCR-1, is not
responsible for hospital-based outbreaks compared with
K. pneumoniae (see the example of ESBL-producing
K. pneumoniae). The very low amounts of polymyxins used in
human medicine will not be a driving force for spreading themcr-
1 gene in human isolates. The ﬁtness cost of MCR-1-mediated
modiﬁcation of the lipopolysaccharide may be as high as shown
for strains expressing chromosome-encoded modiﬁcations of
the lipopolysaccharide [1]. Therefore, MCR-1 producers may be
eliminated rapidly from the gut ﬂora in the absence of selection
pressure with polymyxins. The stability and transferability of the
mcr-1-bearing plasmids may be low and those plasmids do not
harbour many other antibiotic resistance genes (P. Nordmann,
unpublished data). Finally, many MCR-1 producers exhibit low
levels of resistance to polymyxins. Therefore, it is possible that
polymyxins might retain some in vivo activity for treating in-
fections due to MCR-1-producing isolates, either alone or in
association with other antibiotic molecules.
What Should Be Done Now?
Taking into account the massive use of polymyxins in animals
(as they are cheap antibiotics), polymyxins should be banned as
growth promoters worldwide, as was done in Europe as early
as 2005. Restricted use of polymyxins in prophylaxis and
metaphylaxis in animals should also be promoted in a coordi-
nated effort at the international level. Selective digestive
decontamination in humans by using colistin-containing mix-
tures should be revised urgently.
Detection of colistin-resistant bacteria should be encouraged
by promoting the development of reliable techniques for sus-
ceptibility testing such as the broth dilution technique and rapid
diagnostic tests for polymyxin resistance. A precise determination
of susceptibility to polymyxins should be performed at least for all
carbapenemase-producing enterobacterial isolates and for
enterobacterial species that are known to be the source of
nosocomial outbreaks (K. pneumoniae, Enterobacter spp.). Once
MCR-1 producers are detected, the issue of isolation of infected/
carriers will be raised. We believe that patients carrying isolates
that produced MCR-1 in association with carbapenemases should
be strictly isolated whatever the bacterial species and whatever
the cost for the hospital community. Isolation of carriers of isolates
producing MCR-1 only is debatable. While waiting for the results
of further clinical studies, we may suggest not isolating patients
carrying MCR-1-producing E. coli but isolating patients carrying
MCR-1-producing K. pneumoniae and Enterobacter sp. This
recommendation is based on the fact that ESBL-producing E. coli
are not responsible for nosocomial outbreaks in acute settings
whereas ESBL-producing K. pneumoniae and Enterobacter spp. are.
Conclusion
Finally, the identiﬁcation of plasmid-mediated colistin resistance
is certainly bad news. However, if adequate measures are
rapidly taken, both in veterinary and human medicines, it is
possible that the spread of this resistance trait may remain
under control to prevent its further dissemination to bacteria in
immunocompromised patients in hospitals. The preservation of
the efﬁcacy of polymyxins is of utmost importance for those
immunocompromised patients who are already infected by
other multidrug-resistant bacteria.
Funding
This work has been funded by the University of Fribourg,
Switzerland.
2
Transparency Declaration
The authors have no conﬂicts of interest to declare.
References
[1] Falagas ME, Rafailidis PI, Matthaiou DK. Resistance to polymyxins:
mechanisms, frequency and treatment options. Drug Resist Update
2010;13:132–8.
[2] Liu YY, Wang Y, Walsh TR, Yi L-X, Zang R, Spencer J, et al. Emergence
of plasmid-mediated colistin-resistance mechanism MCR-1 in animals
and human beings in China: a microbiological study and molecular
biology study. Lancet Infect Dis 2016. pii:S1473–3099(15)00424-7i.
[3] Poirel L, Kieffer N, Liassine N, Than D, Nordmann P. Plasmid-encoded
carbapenem and colistin resistance in a clinical isolate of Escherichia coli.
Lancet Infect Dis 2016. http://dx.doi.org/10.1016/S1473-3099(16)
00006-2.
[4] Falgenhauer L, Waezsada S-E, Yao Y, Imirzalioglu C, Käsbohrer A,
Roesler U. Colistin resistance gene mcr-1 in extended-spectrum
β-lactamase-producing and carbapenemase-producing Gram-negative
bacteria in Germany. Lancet Infect Dis 2016. http://dx.doi.org/10.1016/
S1473-3099.
[5] Du H, Chen L, Tan TW, Kreiswirth BN. Emergence of the mcr-1 colistin
resistance gene in carbapenem-resistant Enterobacteriaceae. Lancet
Infect Dis 2016. http://dx.doi.org/10.1016/S1473-3099(16)00056-6.
[6] Nordmann P, Lienhard R, Kieffer N, Clerc O, Poirel L. Plasmid mediated
colistin resistance in Escherichia coli in bacteremia in Switzerland. Clin
Infect Dis 2016. pii: ciw124.
[7] Heaenni M, Poirel L, Kieffer N, Châtre P, Saras E, Métayer V, et al. Co-
occurrence of extended-spectrum ß-lactamase and MCR-1 encoding
genes on plasmids. Lancet Infect Dis 2016. http://dx.doi.org/10.1016/
S1473-3099(16)00007-4.
3
